In contrast, the EGFR-targeting antibody cetuximab failed to improve survival in the randomised international Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) study [4]. This evidence concerns the gene EGFR and gastric cancer.